Circulating Gremlin-1 is elevated in systemic sclerosis patients

Area of Science:

• Immunology
• Rheumatology
• Biochemistry

Background:

• Systemic sclerosis is an autoimmune disease characterized by immune activation, vascular issues, and fibrosis.
• Fibroblast activation to myofibroblasts is central to systemic sclerosis pathogenesis.
• Gremlin-1, a bone morphogenetic protein antagonist, plays a role in development and has been implicated in skin fibrosis.

Purpose of the Study:

• To investigate serum Gremlin-1 levels in patients with early diffuse systemic sclerosis.
• To explore the association between Gremlin-1 and clinical manifestations, including interstitial lung disease.

Main Methods:

• Serum samples were collected from 21 early diffuse systemic sclerosis patients and age/sex-matched controls.
• Gremlin-1 levels were quantified using a specific enzyme-linked immunoassay.
• Clinical variables, including interstitial lung disease and modified Rodnan Skin Score, were assessed.

Main Results:

• Serum Gremlin-1 was significantly elevated in early diffuse systemic sclerosis patients compared to controls (p < 0.001).
• Gremlin-1 levels were markedly higher in patients with systemic sclerosis-associated interstitial lung disease (p < 0.0007).
• A weak correlation was observed between circulating Gremlin-1 and the modified Rodnan Skin Score.

Conclusions:

• Elevated serum Gremlin-1 is present in early diffuse systemic sclerosis.
• Gremlin-1 elevation is particularly pronounced in systemic sclerosis-associated interstitial lung disease.
• Gremlin-1 shows potential as a biomarker for systemic sclerosis-associated interstitial lung disease.